Treatment with B.bifidum NCC189 and S17, B.longum NCC2705, and B.lactis NCC362 has a potentially inhibitory effect on LPS-induced NF-κB activation and mRNA expression of TNF-α, IL-8, and cyclooxygenase 2 (Cox-2) in the IECs of IBD patients [103]. The gene discussed is CXCL8; the disease is inflammatory bowel disease.